- Home
- DHIL vs ZURA Comparison
DHIL vs ZURA Comparison
Compare DHIL & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHIL
- ZURA
- Stock Information
- Founded
- DHIL 1990
- ZURA 2022
- Country
- DHIL United States
- ZURA United States
- Employees
- DHIL N/A
- ZURA N/A
- Industry
- DHIL Investment Managers
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHIL Finance
- ZURA Health Care
- Exchange
- DHIL Nasdaq
- ZURA Nasdaq
- Market Cap
- DHIL 392.1M
- ZURA 69.9M
- IPO Year
- DHIL 1995
- ZURA N/A
- Fundamental
- Price
- DHIL $141.40
- ZURA $1.96
- Analyst Decision
- DHIL
- ZURA Buy
- Analyst Count
- DHIL 0
- ZURA 10
- Target Price
- DHIL N/A
- ZURA $12.67
- AVG Volume (30 Days)
- DHIL 25.5K
- ZURA 292.6K
- Earning Date
- DHIL 11-03-2025
- ZURA 11-06-2025
- Dividend Yield
- DHIL 4.24%
- ZURA N/A
- EPS Growth
- DHIL 21.42
- ZURA N/A
- EPS
- DHIL 17.58
- ZURA N/A
- Revenue
- DHIL $151,281,009.00
- ZURA N/A
- Revenue This Year
- DHIL N/A
- ZURA N/A
- Revenue Next Year
- DHIL N/A
- ZURA N/A
- P/E Ratio
- DHIL $8.02
- ZURA N/A
- Revenue Growth
- DHIL 6.29
- ZURA N/A
- 52 Week Low
- DHIL $122.32
- ZURA $0.97
- 52 Week High
- DHIL $173.25
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- DHIL 45.31
- ZURA 51.95
- Support Level
- DHIL $139.55
- ZURA $1.88
- Resistance Level
- DHIL $143.00
- ZURA $2.19
- Average True Range (ATR)
- DHIL 2.41
- ZURA 0.13
- MACD
- DHIL -0.24
- ZURA -0.04
- Stochastic Oscillator
- DHIL 26.36
- ZURA 17.50
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.